Abstract Objective To describe the clinical characteristics and treatment course of a patient diagnosed with Epstein-Barr virus positive diffuse large B-cell lymphoma (EBV + DLBCL) after past pulmonary lesions regressed and contracting COVID-19. Methods We retrospectively analyzed the clinical characteristics and treatment course of a patient diagnosed with EBV + DLBCL, who had previously exhibited pulmonary lesions on PET-CT examination more than 7 years ago, which spontaneously regressed without specific treatment, and subsequently developed COVID-19 infection. Relevant literature was also reviewed. Results The patient's PET-CT examination more than 7 years ago suggested pulmonary lesions suspicious of malignancy, but further treatment was not pursued. Subsequent follow-up CT scans revealed gradual regression of the pulmonary lesions. Three months ago, the patient presented with symptoms of fever, chills, and limb weakness, and was diagnosed with EBV + DLBCL based on cervical lymph node biopsy following COVID-19 pneumonia. After treatment with the Rituximab-mini Cyclophosphamide Doxorubicin Vincristine Prednisone (R-miniCHOP) regimen, the patient's condition improved and was discharged. Conclusion Primary pulmonary lymphoma (PPL) may progress to EBV-positive diffuse large B-cell lymphoma after regression, potentially influenced by COVID-19. Diagnosis of PPL remains challenging in clinical practice, and timely pathological tissue biopsy is the most effective method for identification.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: